Sign Up Today and Learn More About Obsidian Therapeutics Stock
Invest in or calculate the value of your shares in Obsidian Therapeutics or other pre-IPO companies through EquityZen's platform.
Obsidian Therapeutics Stock (OBTH)
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
About Obsidian Therapeutics Stock
Founded
2015
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Obsidian Therapeutics Press Mentions
Stay in the know about the latest news on Obsidian Therapeutics
TIL therapies: the impact on cancer research
labiotech • May 13, 2026
Halper Sadeh LLC is Investigating Whether XOMA, RMAX, GRTX are Obtaining Fair Deals for their Shareholders
globenewswire • May 05, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—XOMA, RMAX, GRTX, and AVNS
globenewswire • May 05, 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--LEG, AVNS, GRTX, and GSAT
prnewswire • Apr 23, 2026
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
businesswire • Apr 22, 2026
Obsidian Therapeutics Management
Leadership team at Obsidian Therapeutics
Senior Vice President & Head of Research
Steve Shamah
CSO
Jan Ter Meulen
Join now and verify your accreditation status to gain access to:
- Obsidian Therapeutics Current Valuation
- Obsidian Therapeutics Stock Price
- Obsidian Therapeutics Management
- Available deals in Obsidian Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Obsidian Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Obsidian Therapeutics Revenue and Financials
- Obsidian Therapeutics Highlights
- Obsidian Therapeutics Business Model
- Obsidian Therapeutics Risk Factors
- Obsidian Therapeutics Research Report from SACRA Research
Trading Obsidian Therapeutics Stock
How to invest in Obsidian Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Obsidian Therapeutics through EquityZen funds. These investments are made available by existing Obsidian Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Obsidian Therapeutics stock?
Shareholders can sell their Obsidian Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 450K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 54K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
